New Prostate Cancer Immunotherapy Shows Promise

New research indicates that immunotherapy may offer benefits for men with localised, high-risk prostate cancer, although it's not yet a standard treatment. A recent Phase 3 clinical trial explored a viral immunotherapy, aglatimagene besadenovec, which is delivered directly to the tumor to kill cancer cells and stimulate an immune response.

This innovative approach aims to enhance radiotherapy's effects. While traditional immune-checkpoint inhibitors are not suitable for localised prostate cancer, this viral therapy represents a novel direction. Early findings from the trial suggest a benefit in disease-free survival. An exploratory analysis indicated that 80% of patients on the experimental therapy were free of tumour cells in biopsies after two years, compared to 63% in the control group.

However, these promising results require further evaluation, as the biopsy outcome was an exploratory analysis. Currently, immunotherapy is primarily used for advanced cancer, but this study explored its potential in early, localised stages. Scientists are investigating if early immune system activation can help eliminate residual disease after primary treatment.

For now, these outcomes are considered positive signs rather than a treatment revolution. Doctors emphasize that individualised treatment decisions remain crucial, considering various patient factors and established therapies like surgery, radiotherapy, and hormonal therapy. The true promise lies in enhancing existing treatments, not replacing them.